Updating and confirming an industry-sponsored pharmacoeconomic model: Comparing two antipsychotics in the treatment of schizophrenia

Value in Health

Volumn 15, Issue 1, 2012, Pages 55-64

  Graham, Christopher N ^a   Mauskopf, Josephine A ^a   Lawson, Anthony H ^b   Ascher Svanum, Haya ^b   Bruhn, David ^c  

^a RTI HEALTH SOLUTIONS   (United States)

^b ELI LILLY AND COMPANY   (United States)

^c GLAXOSMITHKLINE   (United States)

Author keywords

cost effectiveness; economic model; olanzapine; schizophrenia

Indexed keywords

CHOLINERGIC RECEPTOR BLOCKING AGENT; CLOZAPINE; NEUROLEPTIC AGENT; OLANZAPINE; RISPERIDONE; ZIPRASIDONE;

ARTICLE; CLINICAL DECISION MAKING; COST CONTROL; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; DATA ANALYSIS; DRUG COST; DRUG INDUSTRY; DRUG SUBSTITUTION; EXTRAPYRAMIDAL SYMPTOM; FUNDING; HEALTH CARE COST; HEALTH CARE UTILIZATION; HUMAN; HYPOTENSION; LENGTH OF STAY; MAINTENANCE THERAPY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; RANDOMIZED CONTROLLED TRIAL (TOPIC); RELAPSE; SCHIZOPHRENIA; SIDE EFFECT; STATISTICAL MODEL; SUICIDE; SYSTEMATIC REVIEW; TREATMENT RESPONSE; UNITED STATES; WEIGHT GAIN;

ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; COST-BENEFIT ANALYSIS; DECISION SUPPORT TECHNIQUES; ECONOMICS, PHARMACEUTICAL; HEALTH SERVICES; HUMANS; MODELS, ECONOMIC; PIPERAZINES; QUALITY-ADJUSTED LIFE YEARS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECURRENCE; SCHIZOPHRENIA; THIAZOLES;

EID: 84855982984     PISSN: 10983015     EISSN: 15244733     Source Type: Journal    
DOI: 10.1016/j.jval.2011.08.1741     Document Type: Article

References (39)

1. C.B. Baker, M.T. Johnsrud, M.L. Crismon Quantitative analysis of sponsorship bias in economic studies of antidepressants Br J Psychiatry 183 2003 498 506 (Pubitemid 37533195)
2. P. Andlin-Sobocki, B. Jnsson, H.U. Wittchen, J. Olesen Cost of disorders of the brain in Europe Eur J Neurol 12 Suppl. 1 2005 1 27
3. E.Q. Wu, H.G. Birnbaum, L. Shi The economic burden of schizophrenia in the United States in 2002 J Clin Psychiatry 66 2005 1122 1129 (Pubitemid 41442278)
4. A.F. Lehman, J.A. Lieberman, L.B. Dixon Practice guideline for the treatment of patients with schizophrenia, second edition Am J Psychiatry 161 2, Suppl. 2004 1 56
5. I. Alexeyeva, J. Mauskopf, S.R. Earnshaw Comparing olanzapine and ziprasidone in the treatment of schizophrenia: a case study in modeling J Med Econ 4 2001 179 192 (Pubitemid 34027351)
6. T.R. Einarson Pharmacoeconomic applications of meta-analysis for single groups using antifungal onychomycosis lacquers as an example Clin Ther 19 1997 559 569 (Pubitemid 27292595)
7. A. Breier, P.H. Berg, J.H. Thakore Olanzapine versus ziprasidone: results of a 28-week double-blind study in patients with schizophrenia Am J Psychiatry 162 2005 1879 1887 (Pubitemid 41428617)
8. P.D. Harvey, C.O. Siu, S. Romano Randomized, controlled, double-blind, multicenter comparison of the cognitive effects of ziprasidone versus olanzapine in acutely ill inpatients with schizophrenia or schizoaffective disorder Psychopharmacology (Berl) 172 2004 324 332 (Pubitemid 38392326)
9. P.D. Harvey, C.R. Bowie, A. Loebel Neuropsychological normalization with long-term atypical antipsychotic treatment: results of a six-month randomized, double-blind comparison of ziprasidone vs. olanzapine J Neuropsychiatry Clin Neurosci 18 2006 54 63 (Pubitemid 43277257)
10. R.S. Kahn, W.W. Fleischhacker, H. Boter EUFEST study group Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial Lancet 371 2008 1085 1097 (Pubitemid 351418005)
11. B.J. Kinon, I. Lipkovich, S.B. Edwards A 24-week randomized study of olanzapine versus ziprasidone in the treatment of schizophrenia or schizoaffective disorder in patients with prominent depressive symptoms J Clin Psychopharmacol 26 2006 157 162 (Pubitemid 43740339)
12. J.A. Lieberman, T.S. Stroup, J.P. McEvoy Clinical Antipsychotic Trials of Interventions Effectiveness (CATIE) Investigators Effectiveness of antipsychotic drugs in patients with chronic schizophrenia N Engl J Med 353 2005 1209 1223 (Pubitemid 41345943)
13. R.E. McCue, R. Waheed, L. Urcuyo Comparative effectiveness of second-generation antipsychotics and haloperidol in acute schizophrenia Br J Psychiatry 189 2006 433 440 (Pubitemid 44683176)
14. G.M. Simpson, I.D. Glick, P.J. Weiden Randomized, controlled, double-blind multicenter comparison of the efficacy and tolerability of ziprasidone and olanzapine in acutely ill inpatients with schizophrenia or schizoaffective disorder Am J Psychiatry 161 2004 1837 1847 (Pubitemid 39314678)
15. G.M. Simpson, P. Weiden, T. Pigott Six-month, blinded, multicenter continuation study of ziprasidone versus olanzapine in schizophrenia Am J Psychiatry 162 2005 1535 1538 (Pubitemid 41105572)
16. T.S. Stroup, J.A. Lieberman, J.P. McEvoy CATIE Investigators Effectiveness of olanzapine, quetiapine, risperidone, and ziprasidone in patients with chronic schizophrenia following discontinuation of a previous atypical antipsychotic Am J Psychiatry 163 2006 611 622 (Pubitemid 44464570)
17. C.M. Beasley Jr, S.H. Hamilton, A.M. Crawford Olanzapine versus haloperidol: acute phase results of the international double-blind olanzapine trial Eur Neuropsychopharmacol 7 1997 125 137 (Pubitemid 27240346)
18. P. Keck Jr, A. Buffenstein, J. Ferguson Ziprasidone 40 and 120 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: a 4-week placebo-controlled trial Psychopharmacology (Berl) 140 1998 173 184 (Pubitemid 28538477)
19. J. Mauskopf, M. Muroff, P.J. Gibson, D.L. Grainger Estimating the costs and benefits of new drug therapies: atypical antipsychotic drugs for schizophrenia Schizophr Bull 28 2002 619 635 (Pubitemid 36569791)
20. C.S. Palmer, D.A. Revicki, L.A. Genduso A cost-effectiveness clinical decision analysis model for schizophrenia Am J Manag Care 4 1998 345 355 (Pubitemid 28350792)
21. The Essential RBRVS: A Comprehensive Listing of RBRVS Values for CPT and HCPCS Codes 2008 Ingenix, Inc. Salt Lake City, Utah
22. US Department of Labor. Bureau of Labor Statistics Consumer price indexall urban consumers Not seasonally adjusted, US city average, medical care http://data.bls.gov 2009 [Accessed December 23, 2009]
23. National Association of Psychiatric Health Systems (NAPHS) Trends in Psychiatric Health Systems: 1995 Annual Survey, Final Report 1995 National Association of Psychiatric Health Systems Washington, DC 13
24. Ridgewood Financial Institute (RFI) Fee, practice and managed care survey Psychother Finances 21 1995 1 8
25. Red Book for Windows [computer program] Version 61127, Vol.55 2010 Thomson PDR Montvale, NJ
26. P.V. Tran, M.A. Dellva, G.D. Tollefson Oral olanzapine versus oral haloperidol in the maintenance treatment of schizophrenia and related psychoses Br J Psychiatry 172 1998 499 505 (Pubitemid 28247482)
27. R.R. Conley, R. Mahmoud A randomized double-blind study of risperidone and olanzapine in the treatment of schizophrenia or schizoaffective disorder Am J Psychiatry 158 2001 765 774 (Pubitemid 32429846)
28. L.A. Lenert, A.P. Sturley, M.H. Rapaport Public preferences for health states with schizophrenia and a mapping function to estimate utilities from positive and negative syndrome scales Schizophr Res 71 2004 155 165 (Pubitemid 39209485)
29. I. Bitter, M.R. Dossenbach, S. Brook Olanzapine versus clozapine in treatment-resistant or treatment-intolerant schizophrenia Prog Neuropsychopharmacol Biol Psychiatry 28 2004 173 180 (Pubitemid 37548509)
30. B.L. Lambert, F.E. Cunningham, D.R. Miller Diabetes risk associated with use of olanzapine, quetiapine, and risperidone in veterans health administration patients with schizophrenia Am J Epidemiol 164 2006 672 681 (Pubitemid 44453496)
31. M. Smith, D. Hopkins, R.C. Peveler First- v. second-generation antipsychotics and risk for diabetes in schizophrenia: systematic review and meta-analysis Br J Psychiatry> 192 2008 406 411 (Pubitemid 351809892)
32. M.U. Yood, G. DeLorenze, C.P. Quesenberry Jr The incidence of diabetes in atypical antipsychotic users differs according to agent - -results from a multisite epidemiologic study Pharmacoepidemiol Drug Saf 18 2009 791 799
33. R.A. Baker, A. Pikalov, Q.V. Tran Atypical antipsychotic drugs and diabetes mellitus in the US Food and Drug Administration Adverse Event Database: a systematic Bayesian signal detection analysis Psychopharmacol Bull 42 2009 11 31
34. A. Briggs, D. Wild, M. Lees Impact of schizophrenia and schizophrenia treatment-related adverse events on quality of life: direct utility elicitation Health Qual Life Outcomes 6 2008 105
35. B. Strom, G. Faich, S. Eng Comparative mortality associated with ziprasidone vs olanzapine in real-world use: the ziprasidone observational study of cardiac outcomes (ZODIAC) [abstract] Schizophr Res 98 Suppl. 2008 160 161
36. D.L. Leslie, R.A. Rosenheck Pharmacotherapy and health care costs among patients with schizophrenia and newly diagnosed diabetes Psychiatr Serv 56 2005 803 809 (Pubitemid 40967456)
37. N.M. Furiak, H. Ascher-Svanum, R.W. Klein Cost-effectiveness model comparing olanzapine and other atypical antipsychotics in the treatment of schizophrenia in the United States Cost Eff Resour Alloc 7 2009 4
38. F. Farahati, M. Boucher, K. Moulton Overview of Atypical Antipsychotic Monotherapy for Schizophrenia: Clinical Review and Economic Evaluation of First Year of Treatment [Technology overview number 32] 2007 Canadian Agency for Drugs and Technologies in Health Ottawa
39. FDA Psychopharmalogical Drugs Advisory Committee Briefing Document for Zeldox Capsules (Ziprasidone HCl) July 19, 2000